Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination therapy approach for smoking cessation that utilizes three different FDA-approved smoking cessation medications: nicotine replacement therapy, bupropion sustained-release (SR), and varenicline. Each medication works through different mechanisms to help reduce nicotine cravings and withdrawal symptoms. Varenicline acts as a partial agonist at α4β2 neuronal nicotinic acetylcholine receptors, bupropion works through noradrenergic and dopaminergic systems, and nicotine replacement therapy provides controlled doses of nicotine to reduce withdrawal symptoms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on nicotine + bupropion + varenicline.